Loading company…
Develops immunotherapies using a platform focused on cellular and immune interactions.
Valora Therapeutics develops immunotherapies using its AbLec™ platform, which studies sugar-mediated cellular and immune interactions. Its research targets immune-related diseases, including cancer and autoimmune disorders. Founded in 2023, the company is based in La Jolla, US. In November 2024, it raised USD 30 million in seed funding co-led by Avalon Bio Ventures, Bregua Corporation, and TigerGene LLC, with Alexandria Venture Investments and Correlation Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in